# Yuflyma® (Adalimumab), Patient Experience After Switching

> **NCT05427942** · — · UNKNOWN · sponsor: **Celltrion HealthCare France** · enrollment: 300 (estimated)

## Conditions studied

- Rheumatoid Arthritis
- Ankylosing Spondylarthritis
- Axial Spondyloarthritis Without Radiographic Evidence of Ankylosing Spondylitis
- Psoriatic Arthritis
- Crohn Disease
- Ulcerative Colitis

## Interventions

- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT05427942
- **Lead sponsor:** Celltrion HealthCare France
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-03
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-03-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05427942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05427942, "Yuflyma® (Adalimumab), Patient Experience After Switching". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05427942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*